Allogene Takes Step Closer To Off-The-Shelf CAR-Ts
Executive Summary
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
You may also be interested in...
Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.
ASH 2020: Novel CAR-T Approaches Chase BCMA-Targeting Frontrunners
BMS/bluebird and Janssen/Legend have the leading BCMA-targeting CAR-T therapies for multiple myeloma but Poseida, Allogene, CARsgen, Gracell and CBMG are emerging with novel approaches.
'We Jumped' At Opportunity To Take On Pfizer's CAR-T Program, Allogene's Chang Says
Former Kite exec David Chang is keen to use smaller firm's focus to advance allogeneic therapy more rapidly. The start-up acquired Pfizer R&D team along with its allogeneic CAR-T programs and related IP.